adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
Clicks: 209
ID: 132150
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
209 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #13 of 61 articles by views in letters in applied microbiology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano LombardiDepartment of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Naples, ItalyAbstract: Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US Federal Drug Administration approved the use of rhTSH for adjuvant treatment with radioiodine in patients with DTC without evidence of metastatic thyroid cancer. Quality of life was found to be better with rhTSH preparation than with L-thyroxine withdrawal, thereby resulting in benefits for society as a whole. Furthermore, rhTSH for radioiodine remnant ablation results in a longer effective radioiodine half-life within remnant thyroid tissue and a lower specific absorbed dose in the blood and exposure of bone marrow to X-rays. More studies are required to establish the amount of radioiodine to be administered especially in high-risk patients. Keywords: thyroid cancer, thyrotropin, radioiodine (131I) remnant ablation (RRA), quality of life, ray exposure
| Reference Key |
biondi2008biologicsadjuvant
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Bernadette Biondi;Melania Pulcrano;Loredana Pagano;Gaetano Lombardi |
| Journal | letters in applied microbiology |
| Year | 2008 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.